share_log

Eterna Therapeutics Launches Research To Evaluate ERNA-101's Ability To Induce And Modulate Antitumor Immunity In Ovarian And Breast Cancer Models

Eterna Therapeutics Launches Research To Evaluate ERNA-101's Ability To Induce And Modulate Antitumor Immunity In Ovarian And Breast Cancer Models

Eterna Therapeutics啓動研究,評估ERNA-101在卵巢和乳腺癌模型中誘導和調節抗腫瘤免疫的能力
Benzinga ·  12/03 21:38

Eterna Therapeutics Launches Research To Evaluate ERNA-101's Ability To Induce And Modulate Antitumor Immunity In Ovarian And Breast Cancer Models

Eterna Therapeutics啓動研究,以評估ERNA-101在卵巢癌和乳腺癌模型中誘導和調節抗腫瘤免疫的能力

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論